Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Apr;34(4):665–667. doi: 10.1128/aac.34.4.665

Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group.

E J Boyko 1, A Iravani 1, M H Silverman 1, D J Schelling 1, R A Wright 1
PMCID: PMC171664  PMID: 2188590

Abstract

We conducted a randomized controlled trial of orally administered amifloxacin versus trimethoprimsulfamethoxazole (TMP-SMX) as treatments of acute uncomplicated urinary tract infection in women. Amifloxacin at a dosage of 200 mg twice a day appeared as safe and effective as TMP-SMX, but amifloxacin at 400 mg twice a day tended to cause adverse events more frequently than did TMP-SMX.

Full text

PDF
665

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassey C. M., Baltch A. L., Smith R. P. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates. J Antimicrob Chemother. 1986 May;17(5):623–628. doi: 10.1093/jac/17.5.623. [DOI] [PubMed] [Google Scholar]
  2. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  3. Felmingham D., Wall R. A. The comparative activity of twelve 4-quinolone antimicrobials and sulphadiazine against Neisseria meningitidis. Drugs Exp Clin Res. 1985;11(7):427–429. [PubMed] [Google Scholar]
  4. Garcia I., Bodey G. P., Fainstein V., Ho D. H., LeBlanc B. In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients. Antimicrob Agents Chemother. 1984 Sep;26(3):421–423. doi: 10.1128/aac.26.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Neu H. C., Labthavikul P. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent. Diagn Microbiol Infect Dis. 1985 Nov;3(6):469–478. doi: 10.1016/s0732-8893(85)80003-1. [DOI] [PubMed] [Google Scholar]
  6. Pohlod D. J., Saravolatz L. D. In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin. Antimicrob Agents Chemother. 1984 Mar;25(3):377–379. doi: 10.1128/aac.25.3.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med. 1986 Sep;105(3):429–435. doi: 10.7326/0003-4819-105-3-429. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES